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tribute to non-invasive ventilation (NIV) failure. Prevention of delirium may improve the outcome
and success rate of NIV. The aim of the current study was to compare the effects of using
dexmedetomidine and haloperidol for prevention of delirium during NIV.
Patients and methods: Ninety adult intensive care patients of ASA physical status III and IV on
NIV were randomly allocated to three equal groups. Group D (30 patients) received
dexmedetomidine continuous intravenous infusion of 0.2–0.7 lg/kg/h preceded by a loading dose
of 1.0 lg/kg intravenously over 10 min if needed, group H (30 patients) received haloperidol
continuous intravenous infusion of 0.5–2 mg/h preceded by a loading dose of 2.5 mg intravenously
if needed and group P (30 patients) received normal saline infusion. Supplementary sedation or
analgesia was given when needed. Our primary outcome measure was the incidence of delirium.
Duration of non-invasive mechanical ventilation, incidence of endotracheal intubation during
NIV, length of ICU stay, and length of hospital stay, adverse events and mortality were recorded.
Delirium was diagnosed using the Confusion Assessment Method for the ICU (CAM-ICU).
Hemodynamic parameters and respiratory rate were recorded.
Results: The incidence of delirium was significantly lower in dexmedetomidine group 3/30 (10%)
than haloperidol 10/30 (33.3%) and placebo groups 13/30 (43.3%) groups. Duration of NIV was
significantly shorter in dexmedetomidine group than in placebo group and shorter than haloperidol
group. The incidence of endotracheal intubation was significantly less in dexmedetomidine group
compared to placebo and haloperidol groups. The length of ICU and hospital stay was significantly
shorter in dexmedetomidine group compared to haloperidol and placebo groups Bradycardia
occurred significantly more in dexmedetomidine group while prolonged corrected QT (QTc) inter-
val occurred only in haloperidol group (2 patients). A significantly lower incidence of respiratory
474 E.F. Abdelgaleltract infections was noted in dexmedetomidine group. The need for supplementary sedatives and
analgesic was significantly less in dexmedetomidine group compared to haloperidol and placebo
groups.
Conclusion: Dexmedetomidine is more effective than haloperidol for prevention of delirium
during NIV with lower incidence of endotracheal intubation and shorter ICU and hospital stay.
Bradycardia is more frequent with dexmedetomidine use.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-invasive ventilation (NIV) has an increasing role in inten-
sive care due to its benefits in reducing dependence on invasive
mechanical ventilation and associated complications. How-
ever, noninvasive ventilation failure remains a challenging
aspect with rates approaching 40% in some studies [1,2]. Agi-
tation, intolerance, and patient–ventilator asynchrony are fac-
tors implicated in NIV failure for which judicious sedation is
recommended [3].
Delirium is defined in the American Psychiatric Associa-
tion’s (APA) as a disturbance of consciousness and cognition
that develops over a short period of time (hours to days)
and fluctuates over time [4]. Delirium is classified to either
hypoactive (not agitated), hyperactive (agitated), or mixed
[5]. Delirium is common in intensive care unit (ICU) especially
among mechanically ventilated patients. A high prevalence of
delirium and agitation in NIV patients (about 37%) is linked
to a marked increase in the risk of NIV failure [6]. Therefore,
prevention of delirium in ICU patients may be beneficial in
improving the outcome in these patients.
Prevention of delirium depends mainly on non-
pharmacological methods, particularly early mobilization
and noise reduction [7]. The role of sedation in promotion or
prevention of ICU delirium has attracted much comment in
the recent years. Sedatives or opioids may improve patient
comfort and tolerance during NIV but they may induce respi-
ratory depression [8] and sometimes difficult to titrate their
pharmacologic effects because they may accumulate with
repeated dosing. Benzodiazepines may be associated with a
greater risk of delirium and cognitive impairment [9,10].
Dexmedetomidine is an alpha 2 adrenoreceptor agonist
providing sedation and analgesia with attenuation of the stress
response with no significant respiratory depression (12) [11].
Dexmedetomidine was used for sedation and management of
NIV failure in acute respiratory failure patients [12].
Dexmedetomidine has several advantages over other medica-
tions such as narcotics, benzodiazepines, or propofol as a seda-
tive in the ICU. Dexmedetomidine produces minimal
respiratory depression, which facilitates sedation in the nonin-
tubated patients [13].
Haloperidol is a D2 receptors antagonist. Blockade of D2
receptors may result in improvement of hallucination and
delusions. The use of haloperidol can also reduce the need
for sedative and analgesic drugs in ventilated patients. It is rec-
ommended as the drug of choice to treat ICU delirium by the
Society of Critical Care Medicine and American Psychiatry
Association [14]. Haloperidol has a number of side effects,
including extrapyramidal manifestations and rarely neurolep-
tic malignant syndrome but the most dangerous adverse effectis prolongation of the corrected QT (QTc) interval which can
precipitate fatal arrhythmias [15,16].
This study aimed to assess the effects of early use of
dexmedetomidine and haloperidol on incidence of delirium
in patients with NIV and its effects on the duration of NIV
and incidence of endotracheal intubation.2. Patients and methods
2.1. Study design
This prospective, randomized, double blinded controlled study
was carried out after approval of our institutional review
board (IRB) and obtaining informed consent from all patients
or relatives. Ninety adult intensive care patients of ASA phys-
ical status III and IV aged between 26 and 70 years, in zagazig
university hospital from January 2014 to October 2015 were
included in this study. All patients were candidates for
noninvasive mechanical ventilation (NIV). Patients were ran-
domly allocated according to a computer generated random
number into one of three groups (Fig. 1). Group D (30
patients) received dexmedetomidine infusion, group H
(30 patients) received haloperidol infusion and Group P (30
patients) received normal saline infusion. All medications for
the three groups were prepared and labeled by the pharmacist
in 50 ml syringe pumps and they changed the concentration of
the drugs during preparation according to the patient weight
to keep the rate of infusion fixed for the three groups (10 ml
for bolus dose and 2–8 ml/h for continuous infusion). All med-
ications were given by the intensive care staff (physicians and
nurses) that are not involved in the study and are unaware
of the infused drugs for the three groups. Patients in
dexmedetomidine (D) group received Dexmedetomidine con-
tinuous intravenous infusion of 0.2–0.7 lg/kg/h preceded by
a loading dose of 1.0 lg/kg intravenously over 10 min if
needed [if Richmond Agitation Sedation Scale (RASS) was
+2 or more]. In haloperidol (H) group haloperidol was
administered as a continuous intravenous infusion of 0.5–
2 mg/h preceded by a loading dose of 2.5 mg intravenously
over 10 min if needed [if Richmond Agitation Sedation Scale
(RASS) was +2 or more]. Patients in group P received normal
saline continuous intravenous infusion (2–8 ml/h) and a load-
ing dose (10 ml) over 10 min if needed [if Richmond Agitation
Sedation Scale (RASS) was +2 or more].
Supplementary doses of sedatives (midazolam or propofol)
were given to any patient in the studied groups if RASS was
+1 or more. Midazolam was given when RASS was +1 or
+2 and propofol was given when RASS was +3 or +4 or
when patients were still agitated after receiving midazolam.
Figure 1 Flowchart of participants in the study.
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with VAS score P5. The need for supplementary sedation or
analgesia was recorded (the number of patients and the doses
received).
Inclusion criteria were, age more than 18 years, patients
need NIV due to acute exacerbation of acute respiratory fail-
ure in chronic obstructive pulmonary disease (COPD), patients
with acute hypoxemic cardiogenic pulmonary edema and post-
operative respiratory failure patients.
Exclusion criteria included patients or relatives refusal,
patients with known allergy to any of the studied drugs,
patients with known psychiatric disorders or on antipsychotic
medications, patients with severe dementia, patients with heart
rate 650 beats/min or systolic blood pressure 690 mmhg,
patients with prolonged QTc-time (>500 ms) or history of
clinically relevant ventricular arrhythmia, patients with epi-
lepsy or parkinsonism and pregnancy.
Patients were connected to a ventilator (dragger evita4)
(Germany) with a suitable size full face mask (Respironics,
Monroeville, PA, USA). Initial settings of IPAP 10 cms H2O
titrated in increments of 2–3 cm H2O (to a maximum of
20–25 cm H2O) at 5–10 min intervals over the first 30–60 min
according to the clinical response and patient tolerance to
obtain an exhaled tidal volume of 6–8 mL/kg and a respiratory
rate (RR) less than 35 breaths min1. EPAP was adjusted at
4–5 cms H2O and was gradually increased by 2 cm H2O to a
maximum of 10 cm H2O until the FiO2 requirement was 65%
or less to maintain the oxygen saturation above 92%. The
ventilator settings were then adjusted on the basis of pulse
oximetry and serial measurements of arterial blood gases.
Noninvasive ventilation (NIV) and drug sedation were
reduced progressively according to the degree of clinical
improvement and were discontinued if the patient stably main-
tained a RR< 25 breaths min1 and a PaO2/FiO2 > 200.
Endotracheal intubation was indicated at any time during the
study if patient refused or not tolerated noninvasive
ventilation, if partial pressure of arterial carbon dioxide
increased with a pH of 67.20, if patient failed to maintain aPaO2/FiO2 ratio by greater than 150, with severe hemody-
namic instability (defined as a systolic blood pressure of less
than 70 mmHg, or evidence of ischemia or clinically significant
ventricular arrhythmias) and for airway protection (e.g., sei-
zure disorder or vomiting).
Our primary outcome measure was the incidence of
delirium in patients with non-invasive mechanical ventilation.
Secondary outcomes included, the duration of NIV, incidence
of endotracheal intubation during NIV, length of ICU stay,
length of hospital stay, adverse events and mortality.
All patients were monitored by electrocardiography, pulse
oximetry, non-invasive blood pressure (SBP and DBP) and
arterial blood gases. All complications were noted and
recorded. Bradycardia was diagnosed if HR decreased to
660 beats/min and it needed intervention if HR decreased
to 650 beats/min. Hypotension was diagnosed if SBP 6 90
mmhg or DBP 6 60 mmhg. Twelve lead electrocardiography
done if prolonged QTc-time was suspected.
Delirium was diagnosed using the Confusion Assessment
Method for the ICU (CAM-ICU) [17]) where delirium is
diagnosed in two steps (Fig. 2). First step was to assess the
level of consciousness using the Richmond Agitation Sedation
Scale (RASS) [18] [which is a 10-point scale ranging from +4
to 5]. Patients with moderate sedation (RASS score 3) or
more alert should be evaluated for delirium. The CAM-ICU
assesses patients for four features of delirium; three out of four
features are required for a diagnosis of delirium (Fig. 2).
Confusion Assessment Method for the ICU (CAM-ICU) was
performed every four hours.
2.2. Sample size calculation
Power analysis was performed using Chi square test for inde-
pendent samples on frequency of patients complaining of delir-
ium because it was the main outcome variable in the present
study. A pilot study was done before starting this study
because there were no available data in the literature for the
incidence of delirium with dexmedetomidine administration
1:Acute onset of mental status changes or a          
fluctuating course
And                                                            
2:Inattension
Figure 2 Confusion Assessment Method for the ICU (CAM-
ICU).
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delirium of 8% in dexmedetomidine group, and 38% in con-
trol group. Taking power 0.8 and alpha error 0.05, a minimum
sample size of 27 patients was calculated for each group. A
total of patients in each group (30) were included to compen-
sate for possible dropouts (MedCalc 13 for windows, MedCalc
Software bvba, Ostend, Belgium).3. Statistical analysis
Continuous variables were expressed as the mean ± SD and
the categorical variables were expressed as a number (percent-
age). Continuous variables were checked for normality by
using Shapiro-Wilk test. One way ANOVA test was used to
compare three groups of normally distributed data, while
Kruskall Wallis H was used for non-normally distributed data.
Wilcoxon signed rank test was used to compare two dependent
groups of non-normally distributed data. Percent of categori-
cal variables was compared using the Chi-square test. All tests
were two sided. P< 0.05 was considered statistically signifi-
cant. All data were analyzed using Statistical Package for
Social Science for windows version 20.0 (SPSS Inc., Chicago,
IL, USA) & MedCalc for windows version 13 (MedCalc Soft-
ware bvba, Ostend, Belgium) and graphically presented using
Microsoft Office Excel 2010 for windows (Microsoft Cor.,
Redmond, WA, USA).
4. Results
Ninety adult intensive care patients were included in our study
and randomized into three groups. There were no significant
differences among the three groups regarding the baseline
characteristics (p> 0.05) (Table 1).
Regarding the primary and secondary outcomes (Table 2)
the incidence of delirium was significantly lower in dexmedeto-
midine group 3/30(10%) than haloperidol 10/30(33.3%) and
placebo groups 13/30(43.3%) groups. Duration of non-
invasive mechanical ventilation was significantly shorter in
dexmedetomidine group (34.9 ± 8.2 h) than placebo group
(52.9 ± 12.7 h) and shorter than haloperidol group
(39.3 ± 10.2 h) with significantly more patients in placebo
group (14 patients) and halo group (11 patients) required
endotracheal intubation compared to dexmedetomidine group
(4 patients).
The length of ICU stay was significantly shorter in
dexmedetomidine group (3.1 ± 0.4 days) compared to
6.5 ± 1.0 and 6.9 ± 1.2 days in halo and placebo groups
respectively. Also the length of hospital stay was significantly
shorter in dexmedetomidine group (6.2 ± 0.9 days) compared
to 13.5 ± 2.0 and 15.5 ± 2.5 days in haloperidol and placebo
groups respectively. The mortality was lower in both
dexmedetomidine and haloperidol groups (2 patients in each
group) while it was 3 patients in placebo group.
Fig. 3 shows the incidence of complications occurred in the
three studied groups. Bradycardia occurred significantly more
in dexmedetomidine group (8 patients) than in haloperidol
group (2 patients) and placebo group (1 patient). Two patients
in haloperidol group developed prolonged QTc-interval
(>500 ms) (confirmed with 12 lead e c g) which improved with
holding haloperidol for 2 h. No patients in both placebo and
dexmedetomidine groups developed Prolonged QTc interval.
Three patients developed arrhythmia in haloperidol group
compared to 2 patients in both dexmedetomidine and placebo
groups. Hypotension occurred in 4 patients in dexmedeto-
midine group with dose reduction by 50% from the current
dose in 3 of them while hypotension occurred in 3 patients
in both haloperidol and placebo groups. More patients devel-
oped vomiting in haloperidol group (5 patients) compared to 3
patients in both dexmedetomidine and placebo groups.
Table 1 Baseline characteristics.
Baseline characteristics Group D (N= 30) Group H (N= 30) Group P (N= 30) p-value
Age (years) 51.1 ± 8.4 51.0 ± 8.8 49.1 ± 8.0 0.596
Gender (number)
Male/female 24/6 22/8 21/9 0.664§
Diagnosis
Acute exacerbation of acute respiratory failure in COPD* 20 (66.7%) 18 (60%) 21 (70%) 0.888§
Acute hypoxemic cardiogenic pulmonary edema* 4 (13.3%) 6 (20%) 5 (16.7%)
Postoperative respiratory failure patients* 6 (20%) 6 (20%) 4 (13.3%)
APACHE II score in the 24 h immediately prior to enrollment 17.0 ± 2 16.7 ± 1.9 16.8 ± 1.9 0.843
Body mass index kg/m2 25.4 ± 4.6 26.9 ± 5.1 24.3 ± 6.3 0.075
Vital data & ABG
Respiratory rate* 32.3 ± 8.8 32.6 ± 8.8 30.3 ± 9.1 0.424
pH* 7.23 ± 0.08 7.22 ± 0.06 7.23 ± 0.05 0.705*
PaCO2, mm Hg
* 51.6 ± 14.3 53.0 ± 15.9 52.2 ± 14.2 0.938
PaO2, mm Hg
* 87.7 ± 11.1 85.5 ± 11.2 83.9 ± 11.4 0.421*
PaO2/FiO2
* 176.6 ± 32.8 175.1 ± 27.0 174.6 ± 30.3 0.985
N= Total number of patients in each group; quantitative data were expressed as the mean ± SD; qualitative data were expressed as a number
(percentage).
 Kruskall Wallis H test.
* One Way ANOVA test.
§ Chi-square test; p < 0.05 is significant.
Table 2 Primary and secondary outcomes in the three groups.
Outcomes Group D (N= 30) Group H (N= 30) Group P (N= 30) p-value
Incidence of delirium (1ry outcome) 3 (10%)*,] 10 (33.3%) 13 (43.3%) 0.014§
Duration of NIV (h) 34.9 ± 8.2] 39.3 ± 10.2– 52.9 ± 12.7 <0.001
Incidence of endotracheal intubation 4 (13.3%)*,] 11 (36.7%) 14 (46.7%) 0.018§
Length of ICU stay (days) 3.1 ± 0.4*,] 6.5 ± 1.0 6.9 ± 1.2 <0.001
Length of hospital stay (days) 6.2 ± 0.9*,] 13.5 ± 2.0– 15.5 ± 2.5 <0.001
Mortality 2 (6.7%) 2 (6.7%) 3 (10%) 0.856§
N = Total number of patients in each group; quantitative data were expressed as the mean ± SD; qualitative data were expressed as a number
(percentage).
 Kruskall Wallis H test.
§ Chi-square test; p < 0.05 is significant.
* Significant difference between group D and group H.
] Significant difference between group D and group P.
– Significant difference between group H and group P.
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was noted in dexmedetomidine group (2 patients) compared
to haloperidol (9 patients) and placebo groups (10 patients).
The need for supplementary sedatives and analgesics is
shown in Table 3. A significantly lower number of patients
(2 patients) in dexmedetomidine group needed midazolam with
a total dose of 5.5 ± 1.0 mg than haloperidol group
(8 patients) needed 13.5 ± 1.9 mg and placebo group
(11 patients) needed 30 ± 4.8 mg. Also propofol was
significantly less needed in dexmedetomidine group (3 patients)
needed 320.2 ± 88.2 mg compared to haloperidol group
(10 patients) needed 680.1 ± 162.2 mg and placebo groups
(13 patients) needed 1151.4 ± 241.9 mg. Fentanyl was
significantly less needed in dexmedetomidine group
(2 patients needed 100.5 ± 29.4 mcg) compared to 8 patients
(351.6 ± 88.2 mcg) in haloperidol group and 10 patients
(480.1 ± 117.2 mcg) in placebo group.Fig. 4 shows the hemodynamic parameters and
respiratory rate in the 3 studied groups. There were no
significant differences in baseline measurements between
the three studied groups. Both SBP and DBP were signifi-
cantly lower after 30 min and 1 h in dexmedetomidine
group when compared to the baseline readings. Also SBP
and DBP were significantly lower in dexmedetomidine
group after 30 min and 1 h when compared to haloperidol
and placebo groups. There was no significant difference
between the 3 studied groups regarding the respiratory rate.
Patients in dexmedetomidine group had a significantly lower
H R for 8 h when compared to baseline measurement.
Heart rate was significantly lower in dexmedetomidine
group compared to the placebo group after 30 min, 1 h,
2 h, and 4 h. Also HR was significantly lower in
dexmedetomidine group after 30 min, 1 h and 2 h compared
to haloperidol group.
Figure 3 Bar chart shows incidence of complications in the three groups. * Significant difference between group D and group
H. ] Significant difference between group D and group P. – Significant difference between group H and group P.
Table 3 Supplementary sedatives and analgesic needs during NIV.
Supplementary sedatives and analgesics Group D (N= 30) Group H (N= 30) Group p (N= 30) p-value
Midazolam
No of patients 2 (6.7%)*,] 8 (26.7%) 11 (36.7%) 0.020§
Total dose (mg) 5.5 ± 1.0*,] 13.5 ± 1.9– 30 ± 4.8 <0.001
Propofol
No of patients 3 (10%)*,] 10 (33.3%) 13 (43.3%) 0.014§
Total dose (mg) 320.2 ± 88.2*,] 680.1 ± 162.2– 1151.4 ± 241.9 <0.001
Fentanyl
No of patients 2 (6.7%)*,] 8 (26.7%) 10 (33.3%) 0.035§
Total dose (mcg) 100.5 ± 29.4*,] 351.6 ± 88.2– 480.1 ± 117.2 <0.001
N= Total number of patients in each group; quantitative data were expressed as the mean ± SD; qualitative data were expressed as a number
(percentage).
 Kruskall Wallis H test.
 One Way ANOVA test.
§ Chi-square test; p< 0.05 is significant.
* Significant difference between group D and group H.
] Significant difference between group D and group P.
– Significant difference between group H and group P.
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Non-invasive mechanical ventilation supports breathing with-
out the need for intubation and has the added advantage of
lower needs for sedation. Prevention of agitation and delirium
during NIV can decrease the incidence of endotracheal intuba-
tion and invasive mechanical ventilation.
In the present study we compared the effects of early pro-
phylactic use of dexmedetomidine or haloperidol on the inci-
dence of delirium during NIV. We also studied the effects of
the studied drugs on the duration of NIV and the incidenceof NIV failure with need of endotracheal intubation and the
length of ICU and hospital stay.
The incidence of delirium was significantly lower in
dexmedetomidine group than haloperidol and placebo groups.
This may be due to the state of cooperative sedation and anal-
gesia without effect on the respiratory drive produced by
dexmedetomidine. These criteria with dexmedetomidine use
contribute to less need for supplementary sedatives and anal-
gesic that may have a role in occurrence of delirium. Incidence
of delirium was also lower in haloperidol group compared to
placebo group. In a study compared haloperidol with placebo
Figure 4 Marker and error bar chart shows SBP (mmHg), DBP (mmHg), HR (beat/min) and RR (Breath/min) at various times of
measurements of the studied groups; markers represent mean; Y-error bar represents ±1SD. * Significant difference between group D and
group H. ] Significant difference between group D and group P. – Significant difference between group H and group P.  Significant
difference in comparison with baseline measurement.
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480 E.F. Abdelgalelas a prophylactic therapy for the prevention of postoperative
delirium in elderly hip surgery patients the severity and dura-
tion of delirium were reduced but the incidence of delirium
was not altered by haloperidol compared to placebo [19].
Duration of non-invasive mechanical ventilation was signif-
icantly shorter in dexmedetomidine group than placebo group
with more patients required endotracheal intubation in pla-
cebo group (14 patients) compared to dexmedetomidine group
(4 patients). Also the duration of NIV and number of patients
required endotracheal intubation was less in dexmedetomidine
group than haloperidol group. The length of ICU stay and the
hospital stay were significantly shorter in dexmedetomidine
group compared to haloperidol and placebo groups. This
reduced duration of NIV and incidence of endotracheal intu-
bation with shorter ICU and hospital stay in dexmedetomidine
group may be due to the lower incidence of agitation and delir-
ium in dexmedetomidine treated group with decreased compli-
cations related to invasive mechanical ventilation. In a study
that compared use of dexmedetomidine versus midazolam in
patients with NIV failure [20] they found that Dexmedeto-
midine shortened the duration of mechanical ventilation and
the length of the ICU stay with lower incidence of nosocomial
infections. Another study [21] revealed that dexmedetomidine
significantly shortened time to extubation and decreased ICU
length of stay when compared to haloperidol in delirious intu-
bated patients who were difficult to wean from mechanical
ventilation mainly because of agitation and delirium. Another
study [22] compared early use of dexmedetomidine with pla-
cebo during NIV in patients with acute respiratory failure
and found that dexmedetomidine did not improve NIV toler-
ance but this study was limited only to patients with acute res-
piratory failure and started the dexmedetomidine within 8 h of
NIV and not immediately with initiation of NIV like our study
without using any initial bolus dose. This study also included a
small number of patients.
Bradycardia and hypotension associated with dexmedeto-
midine use are due to reduced sympathetic flow and activation
of a2-receptors and are more common with bolus doses and
high maintenance doses (>0.7 lg/kg/h) [23,24]. In our study
more patients in dexmedetomidine group developed
bradycardia compared to the baseline reading and the other
two groups but none of these patients required intervention
as no drop of heart rate 650 beats/min. Hypotension occurred
in dexmedetomidine group in the first hour after starting the
drug and it was mostly in patients received bolus doses. Only
dose reduction by 50% in 3 patients was done but no discon-
tinuation of the drug was needed. Senoglu et al. [25] compared
dexmedetomidine and midazolam for sedation during NIV
and found that dexmedetomidine causes bradycardia and
hypotension which lasted for 2 h after starting dexmedetomi-
dine. We can reduce the occurrence of bradycardia and
hypotension with dexmedetomidine by slow titration of the
drug and minimize the use of bolus doses.
Two patients in haloperidol group developed prolonged
QTc-interval (>500 ms) (confirmed with 12 lead e c g) which
improved with holding haloperidol for 2 h. The incidence of
respiratory tract infection was significantly lower in
dexmedetomidine group. This can be attributed to the lower
incidence of endotracheal intubation and invasive mechanical
ventilation and less need for supplementary sedation and anal-
gesia with better cough and clearance of respiratory secretions.Need for supplementary sedation and analgesia (midazo-
lam, propofol and fentanyl) was significantly lower in
dexmedetomidine group than both haloperidol and placebo
groups. This lower need for supplementary sedation and anal-
gesia with dexmedetomidine may be a contributing factor for
the lower incidence of delirium and endotracheal intubation
with shorter stay in ICU associated with the use of dexmedeto-
midine. Another study [22] compared dexmedetomidine with
placebo for patients with acute respiratory failure and revealed
that routine early use of low dose dexmedetomidine during
NIV does not improve overall tolerance of NIV with non-
significant difference between the two studied groups regarding
needs for supplementary sedation and analgesia. But this study
included a smaller number of patients and was limited to
patients with acute respiratory failure without use of initial
bolus dose and slow change of infusion rate.6. Conclusion
Dexmedetomidine is more effective than haloperidol for
prevention of delirium during NIV with lower incidence of
endotracheal intubation and NIV failure and lower need for
supplementary sedation and analgesia. The length of ICU
and hospital stay was significantly shorter in dexmedetomidine
group with a lower incidence of respiratory tract infections.
Bradycardia is more frequent with dexmedetomidine use.
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